We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Impax Receives 483s at Separate Manufacturing Plants
Impax Receives 483s at Separate Manufacturing Plants
Impax received two Form 483s less than a week apart for poor inspections of two manufacturing facilities, igniting fresh doubts on the company’s plan to win approval of its Parkinson’s drug Rytary.